Teva Pharmaceutical Industries Limited (NYSE:TEVA) EVP Matthew Shields Sells 6,206 Shares

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the transaction, the executive vice president now owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $0.33 during trading hours on Friday, reaching $17.58. 3,817,021 shares of the stock were exchanged, compared to its average volume of 10,110,417. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a market cap of $19.93 billion, a P/E ratio of -12.11, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The stock has a 50 day moving average of $15.67 and a two-hundred day moving average of $17.38.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter last year, the business posted $0.48 EPS. The firm's revenue for the quarter was up 1.9% on a year-over-year basis. Equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $29,000. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth $39,000. New Age Alpha Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $44,000. Finally, Compagnie Lombard Odier SCmA acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday. They set a "buy" rating and a $24.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $24.44.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.